$0.7879
-0.05-6.50%
At close: -
$0.7800
-0.00790-1.00%
After Hours: Apr 25, 7:56 PM EDT
Comments
Loading...
Plus Therapeutics Analyst Ratings and Price Targets | NASDAQ:PSTV | Benzinga
Plus Therapeutics Inc has a consensus price target of $10.3 based on the ratings of 5 analysts. The high is $20 issued by Ascendiant Capital on April 21, 2025. The low is $5 issued by JonesTrading on October 7, 2022. The 3 most-recent analyst ratings were released by Ascendiant Capital, HC Wainwright & Co., and D. Boral Capital on April 21, 2025, March 28, 2025, and March 28, 2025, respectively. With an average price target of $11.5 between Ascendiant Capital, HC Wainwright & Co., and D. Boral Capital, there's an implied 1374.36% upside for Plus Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Ascendiant Capital
HC Wainwright & Co.
D. Boral Capital
Maxim Group
JonesTrading
1calculated from analyst ratings
Analyst Ratings for Plus Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/21/2025 | Buy Now | 2464.1% | Ascendiant Capital | Edward Woo53% | $19 → $20 | Maintains | Buy | Get Alert |
| 03/28/2025 | Buy Now | 605.13% | HC Wainwright & Co. | Sean Lee68% | $8 → $5.5 | Maintains | Buy | Get Alert |
| 03/28/2025 | Buy Now | 1053.85% | D. Boral Capital | Jason Kolbert44% | $9 → $9 | Maintains | Buy | Get Alert |
| 03/21/2025 | Buy Now | 1053.85% | D. Boral Capital | Jason Kolbert44% | $9 → $9 | Maintains | Buy | Get Alert |
| 03/17/2025 | Buy Now | 1053.85% | D. Boral Capital | Jason Kolbert44% | → $9 | Initiates | → Buy | Get Alert |
| 12/09/2024 | Buy Now | 2335.9% | Ascendiant Capital | Edward Woo53% | $20 → $19 | Maintains | Buy | Get Alert |
| 11/26/2024 | Buy Now | 925.64% | HC Wainwright & Co. | Sean Lee68% | → $8 | Reiterates | Buy → Buy | Get Alert |
| 11/15/2024 | Buy Now | 925.64% | HC Wainwright & Co. | Sean Lee68% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 09/03/2024 | Buy Now | 2464.1% | Ascendiant Capital | Edward Woo53% | $21 → $20 | Maintains | Buy | Get Alert |
| 08/16/2024 | Buy Now | 925.64% | HC Wainwright & Co. | Sean Lee68% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 08/15/2023 | Buy Now | 925.64% | HC Wainwright & Co. | Sean Lee68% | → $8 | Reiterates | Buy → Buy | Get Alert |
| 08/14/2023 | Buy Now | 925.64% | HC Wainwright & Co. | Sean Lee68% | → $8 | Reiterates | Buy → Buy | Get Alert |
| 06/30/2023 | Buy Now | 925.64% | HC Wainwright & Co. | Sean Lee68% | $3.5 → $8 | Maintains | Buy | Get Alert |
| 05/03/2023 | Buy Now | 1438.46% | Maxim Group | Jason McCarthy42% | $30 → $12 | Maintains | Buy | Get Alert |
| 04/21/2023 | Buy Now | 348.72% | HC Wainwright & Co. | Sean Lee68% | → $52.5 | Reiterates | → Buy | Get Alert |
| 02/27/2023 | Buy Now | 348.72% | HC Wainwright & Co. | Sean Lee68% | → $52.5 | Reiterates | → Buy | Get Alert |
| 10/07/2022 | Buy Now | 541.03% | JonesTrading | Justin Walsh42% | → $75 | Initiates | → Buy | Get Alert |
| 07/22/2022 | Buy Now | 348.72% | HC Wainwright & Co. | Sean Lee68% | $105 → $52.5 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Plus Therapeutics (PSTV) stock?
The latest price target for Plus Therapeutics (NASDAQ:PSTV) was reported by Ascendiant Capital on April 21, 2025. The analyst firm set a price target for $20.00 expecting PSTV to rise to within 12 months (a possible 2464.10% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Plus Therapeutics (PSTV)?
The latest analyst rating for Plus Therapeutics (NASDAQ:PSTV) was provided by Ascendiant Capital, and Plus Therapeutics maintained their buy rating.
When was the last upgrade for Plus Therapeutics (PSTV)?
There is no last upgrade for Plus Therapeutics
When was the last downgrade for Plus Therapeutics (PSTV)?
There is no last downgrade for Plus Therapeutics.
When is the next analyst rating going to be posted or updated for Plus Therapeutics (PSTV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Plus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Plus Therapeutics was filed on April 21, 2025 so you should expect the next rating to be made available sometime around April 21, 2026.
Is the Analyst Rating Plus Therapeutics (PSTV) correct?
While ratings are subjective and will change, the latest Plus Therapeutics (PSTV) rating was a maintained with a price target of $19.00 to $20.00. The current price Plus Therapeutics (PSTV) is trading at is $0.78, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
